Category - Developments

Developments

Rigel Pharma in pact with Grifols to commercialize fostamatinib in Europe

Rigel Pharmaceuticals (NASDAQ:RIGL) entered an exclusive license and supply agreement with Grifols (MCE:GRF; MCE:GRF.P; NASDAQ:GRFS) of Spain to commercialize fostamatinib disodium hexahydrate in all potential...

January 23, 2019

Developments

Blood protein may predict progression of pre-symptomatic Alzheimer’s disease

Researchers in Germany have identified a blood protein marker that can predict the progression of neurodegenerative diseases, including Alzheimer’s disease (AD). The test can detect thisbiomarker in the blood up to 16...

January 23, 2019

Developments

Vessi Medical posts positive preclinical surface cryoablation results for bladder cancer

Closely-held Vessi Medical, a member of Israel’s Trendlines Group (OTCQX:TRNLY; SGX:42T), reported a successful animal study demonstrating the use of its surface cryoablation therapy inside the urinary bladder...

January 22, 2019

Developments

FDA accepts Aerie Pharma IND for dexamethasone Intravitreal Implant

The FDA accepted Aerie Pharmaceuticals’ (NASDAQ:AERI) IND for AR-1105, its dexamethasone intravitreal implant for treatment of macular edema due to retinal vein occlusion. Aerie expects to initiate a Phase 2 clinical...

January 17, 2019

Developments

Adamas Finance subscribes for $5-million of PharmaJet bonds

Adamas Finance Asia intends to subscribe for up to $5-million in a convertible bond offering by closely-held PharmaJet, the maker of needle-free injection devices. The PharmaJet injectors have received FDA approval, CE...

January 17, 2019

Developments

Canopy Growth receives NY hemp license; plans to establish U.S. commercial operations

Canopy Growth (TSX:WEED) (NYSE:CGC) received a licence from New York State to process and produce hemp and will establish large-scale hemp extraction and product manufacturing in the state. Subject to board approval of...

January 14, 2019

Developments

IntelGenx, Tilray working to launch cannabis-infused VersaFilm in late-2019

IntelGenx (TSXV:IGX; OTCQX:IGXT) updated its cannabis-infused VersaFilm product co-development program with Tilray (NASDAQ:TLRY), following recently proposed Government of Canada amendments to the Cannabis Act that...

January 14, 2019

Developments

Echelon reiterates Profound Medical as Top Pick

Echelon Wealth Partners reiterated Profound Medical’s Top Pick status (TSX:PRN; OTCQX:PRFMF) and maintained its “buy” rating and $3 price target. The stock closed at 74 cents on Jan. 9. Analyst Doug Loe writes that...

January 10, 2019

Developments

Fibrocor, Galapagos NV in development pact for fibrotic diseases

Closely-held Fibrocor Therapeutics, and Galapagos NV (Euronext, NASDAQ:GLPG), of Belgium formed a partnership for the development of therapeutics to treat fibrotic diseases of the kidney and other organs. In 2017, MaRs...

January 8, 2019

Developments

Canopy Growth updates U.S. hemp, CBD operations

Following passage of the U.S. 2018 Farm Bill, Canopy Growth (NYSE:CGC;TSX: WEED) provided an update of its hemp operations and expanded pathways to the American market for hemp-based products, including CBD products...

January 8, 2019

Category - Developments

Rigel Pharma in pact with Grifols to commercialize fostamatinib in Europe

Blood protein may predict progression of pre-symptomatic Alzheimer’s disease

Vessi Medical posts positive preclinical surface cryoablation results for bladder cancer

FDA accepts Aerie Pharma IND for dexamethasone Intravitreal Implant

Adamas Finance subscribes for $5-million of PharmaJet bonds

Canopy Growth receives NY hemp license; plans to establish U.S. commercial operations

IntelGenx, Tilray working to launch cannabis-infused VersaFilm in late-2019

Echelon reiterates Profound Medical as Top Pick

Fibrocor, Galapagos NV in development pact for fibrotic diseases

Canopy Growth updates U.S. hemp, CBD operations

General

More